PPARA and fatty liver disease: Diet-induced obese mice treated with a PPARα agonist improved hepatic steatosis accompanied by enhancement of the hepatocyte ultrastructure favoring β-oxidation and decrease in hepatic de novo lipogenesis7, but no study has compared miR-21 KO to PPARα agonist treatment.